Xconomy - Podcasts powered by Odiogo Unknown

Biogen Idec’s scientists have a vision for regenerative medicine, and it has nothing to do with what’s been written and said about embryonic stem cells.
Deep in Biogen’s pipeline, on the verge of entering clinical trials, are a pair of regenerative medicines that the company hopes will become trailblazers in the world of neurological diseases. [...]Click here to play

The global cleantech industry stayed on a bull run despite a shaky economy in 2008, but the momentum is bound to slow down this year. That was the key finding from a report released yesterday by Portland, OR-based Clean Edge, a consulting firm.
The three major clean energy sectors—solar photovoltaics, wind power, and biofuels—saw their combined [...]Click here to play

Focus groups are such a standard part of our market-driven culture that they’ve long since become the subject of parody. Decision-makers are seen as being afraid to act without consulting them; surely, no political party would pick a candidate, no legislator would introduce a big policy initiative, and no movie studio would green-light a big-budget [...]Click here to play

Qualcomm said today the Korean Fair Trade Commission has made allegations about “the lawfulness of certain business practices.” The company says the allegations, set forth in a case examiner’s report, relate to Qualcomm’s integration of multimedia technologies into its chipsets, which are widely used in cell phones, along with “rebates and discounts provided to its [...]Click here to play

Entrepreneur resource site Seattle 2.0 has announced it is hosting a startup awards ceremony on May 7 at the Pacific Science Center in Seattle. Nominations are open from now until March 25 in 10 categories including best startup, best venture capitalist, best angel investor, and best startup technologist. Finalists will be selected by a panel [...]Click here to play

The Obama campaign, and subsequently his administration, had been hinting for a long time that it would allow researchers to use federal funds to study human embryonic stem cell “lines” which had, under the policies of President Bush, been legal to study only with private funding. Considering the relatively small number of scientists [...]Click here to play